CRIS Current Research Information System

NANNI, PATRIZIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.984
AS - Asia 4.720
EU - Europa 3.860
AF - Africa 340
SA - Sud America 230
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 6
Totale 15.149
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.892
VN - Vietnam 1.527
CN - Cina 1.239
SG - Singapore 1.096
IT - Italia 889
GB - Regno Unito 884
DE - Germania 471
HK - Hong Kong 316
SE - Svezia 314
FR - Francia 221
RU - Federazione Russa 206
IN - India 185
UA - Ucraina 180
BR - Brasile 161
CH - Svizzera 143
IE - Irlanda 122
NL - Olanda 114
CI - Costa d'Avorio 113
ZA - Sudafrica 106
JP - Giappone 90
CA - Canada 65
EE - Estonia 58
FI - Finlandia 57
TG - Togo 56
KR - Corea 53
BG - Bulgaria 44
BE - Belgio 43
AR - Argentina 33
ID - Indonesia 26
SC - Seychelles 26
PH - Filippine 25
TH - Thailandia 21
JO - Giordania 19
TR - Turchia 19
IQ - Iraq 17
LT - Lituania 17
MX - Messico 17
BD - Bangladesh 15
PL - Polonia 15
RO - Romania 15
EC - Ecuador 13
TW - Taiwan 13
AT - Austria 12
NG - Nigeria 11
PK - Pakistan 11
EG - Egitto 10
CL - Cile 9
ES - Italia 9
GR - Grecia 8
HR - Croazia 8
AU - Australia 7
SA - Arabia Saudita 7
AE - Emirati Arabi Uniti 5
CO - Colombia 5
DK - Danimarca 5
IR - Iran 5
MA - Marocco 5
EU - Europa 4
MY - Malesia 4
UZ - Uzbekistan 4
VE - Venezuela 4
AZ - Azerbaigian 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
PE - Perù 3
PS - Palestinian Territory 3
PT - Portogallo 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
GH - Ghana 2
KE - Kenya 2
KG - Kirghizistan 2
KH - Cambogia 2
KZ - Kazakistan 2
LB - Libano 2
LI - Liechtenstein 2
LV - Lettonia 2
MD - Moldavia 2
TN - Tunisia 2
AM - Armenia 1
AO - Angola 1
BO - Bolivia 1
BY - Bielorussia 1
ET - Etiopia 1
GI - Gibilterra 1
GP - Guadalupe 1
HU - Ungheria 1
IL - Israele 1
JM - Giamaica 1
LU - Lussemburgo 1
MK - Macedonia 1
MN - Mongolia 1
NI - Nicaragua 1
NP - Nepal 1
NR - Nauru 1
NZ - Nuova Zelanda 1
Totale 15.138
Salva come PNG Salva come JPEG
Città #
Singapore 736
Southend 719
Fairfield 685
Ashburn 619
Chandler 528
Ho Chi Minh City 331
Wilmington 317
Woodbridge 310
Houston 308
Hong Kong 301
Ann Arbor 296
Hanoi 284
Seattle 256
Bologna 239
San Jose 218
Cambridge 205
Dong Ket 191
Santa Clara 182
Shanghai 182
Princeton 175
Beijing 134
Hefei 125
Dublin 122
Boardman 119
Jacksonville 116
Abidjan 113
Bern 113
Council Bluffs 83
Dallas 78
Lauterbourg 77
Nanjing 75
Tokyo 74
Westminster 74
Los Angeles 66
Padova 66
Milan 60
Lomé 56
Berlin 55
Bremen 50
Haiphong 48
Guangzhou 46
New York 45
Jinan 44
Helsinki 43
Sofia 43
Saint Petersburg 42
Brussels 41
Seoul 39
Buffalo 37
San Diego 37
Shenyang 37
Redwood City 36
Da Nang 35
Frankfurt am Main 34
Johannesburg 34
London 30
Nanchang 28
Redmond 28
Redondo Beach 28
Changsha 27
Hebei 26
Turin 26
Tianjin 25
Mülheim 24
Casalecchio di Reno 23
Phoenix 23
Falkenstein 22
Jakarta 22
Amsterdam 21
Ottawa 21
São Paulo 21
Toronto 20
Amman 19
Jiaxing 19
Hải Dương 18
Zhengzhou 18
Falls Church 17
Rome 17
Bulle 15
Mahé 15
Bengaluru 14
Biên Hòa 14
Des Moines 14
Hangzhou 13
Montreal 13
Can Tho 12
Shijiazhuang 12
Haikou 11
Yubileyny 11
Abeokuta 10
Atlanta 10
Bắc Giang 10
Bến Tre 10
Nuremberg 10
Stockholm 10
Verona 10
Warsaw 10
Bühl 9
Dearborn 9
Ha Long 9
Totale 10.153
Salva come PNG Salva come JPEG
Nome #
IFN-γ and CD38 in Hyperprogressive Cancer Development 427
Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER-2. 380
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft 338
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations 317
Different mtDNA mutations modify tumor progression in dependence of the degree of respiratory complex I impairment 265
A multi-DNA preventive vaccine for p53/Neu driven cancer syndrome 265
Respiratory complex I is essential to induce a Warburg profile in mitochondria-defective tumor cells 257
Preclinical therapy of disseminated HER-2+ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. 245
Cancer Vaccines Co-Targeting HER2/Neu and IGF1R 244
A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors 241
Rethinking herpes simplex virus: the way to oncolytic agents. 232
Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases 232
Virus-like particle display of HER2 induces potent anti-cancer responses 229
Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2−/−;Il2rg−/− Mice and Treatment with PI3K Inhibitor 227
A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy 226
Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. 216
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression 212
CD99 Acts as an Oncosuppressor in Osteosarcoma. 211
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1- rearranged NSCLC 210
Apc10.1: an ApcMin/+ intestinal cell line with retention of heterozygosity. 210
Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy 209
Functional evaluation of circulating anti-cancer antibodies with a 3D tumor cell growth inhibition assay 204
Cancer immunoprevention: from mice to early clinical trials 203
Endothelin-3 production by human rhabdomyosarcoma: A possible new marker with a paracrine role. 201
Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model 201
HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines 197
In silico modeling and in vivo efficacy of cancer preventive vaccinations 197
Evaluation of metastatic burden and recovery of human metastatic cells from a mouse model 191
A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene MTND1, an Oncojanus Function 190
Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis 187
Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice. 185
Human responses against HER-2-positive cancer cells in human immune system-engrafted mice. 185
Antimetastatic activity of a preventive cancer vaccine. 185
Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis 184
High metastatic efficiency of human sarcoma cells in Rag2/gamma c double knockout mice provides a powerful test system for antimetastatic targeted therapy 184
Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. 182
Herpesviruses as oncolytic agents 179
Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy 178
Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. 177
Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes? 176
CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity 176
Modeling the competition between lung metastases and the immune system using agents. 175
HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response 175
Oncolytic herpes virus retargeted to HER-2. 174
OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis 174
Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells 171
Immunoprevention and immunotherapy of mammary carcinoma 171
Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas 169
Vaccines for tumour prevention 164
The Promise of Preventive Cancer Vaccines 164
Immunological prevention of a multigene cancer syndrome 164
Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab. 163
Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis. 160
Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. 158
Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma 157
Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario. 157
The molecular basis of herpesviruses as oncolytic agents. 157
Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers. 156
New target antigens for cancer immunoprevention 152
HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy 150
Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells 149
Preclinical HER-2 Vaccines: From Rodent to Human HER-2 148
Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent 147
2011: the immune hallmarks of cancer 147
Preclinical vaccines against mammary carcinoma. 147
Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing’s sarcoma. 146
Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12 engineered allogeneic cell vaccine 145
Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system 144
Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer 143
Targeting CD99 in association with doxorubicin: An effective combined treatment for Ewing’s sarcoma 142
Molecular and cellular biology of rhabdomyosarcoma 140
Insulin-like growth factor binding protein 3 as an anti-cancer molecule in Ewing's sarcoma. 139
Vaccines and other immunological approaches for cancer immunoprevention 135
Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer 132
CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. 121
Immunoprevention 120
Cancer biology, what we know and what we don't know. 117
Methods of treating bone cancer 113
null 99
Immunoprevention of cancer 99
Vaccini contro i tumori 96
Immunotherapy 94
Cancer immunoprevention 82
Development of cellular models expressing cynomolgus (Macaca fascicularis) HER2 for the functional evaluation of cross-reactive anti-human HER2 response 70
Functional stability, progression and evolution of targeted drug sensitivity of HER-2-positive breast cancer patient-derived xenografts 64
null 62
Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells. 49
Totale 15.456
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.708
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.708
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021552 0 0 0 0 0 0 0 0 0 72 65 415
2021/20221.689 161 67 145 82 155 110 51 111 73 115 367 252
2022/20231.986 233 238 106 271 137 137 65 104 261 106 161 167
2023/2024637 22 75 45 51 37 75 35 217 10 27 14 29
2024/20251.954 153 223 154 102 334 134 125 85 22 134 93 395
2025/20264.321 496 455 395 350 475 245 403 145 961 396 0 0
Totale 15.456